Actively Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
200
Participants Needed
6
Research Sites
268 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
CONDITIONS
Official Title
A Study of JNJ-87890387 for Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have histologically or cytologically confirmed metastatic or unresectable solid tumor of one of the following types: renal cell cancer-clear cell or papillary carcinoma; endometrioid ovarian cancer; endometrioid uterine carcinoma; colorectal adenocarcinoma; lung adenocarcinoma
- Have measurable or evaluable disease: Part 1 requires either measurable or evaluable disease; Part 2 requires at least 1 measurable lesion per RECIST v1.1 or evaluable disease with CA 125 greater than 2 times upper limit of normal for ovarian cancer without measurable lesion
- Consent to provide an archived tumor tissue sample at screening
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening
- Be willing and able to adhere to the lifestyle restrictions specified in the protocol
You will not qualify if you...
- Active central nervous system involvement except locally treated brain metastases that are stable and asymptomatic for more than 2 weeks and off or on low-dose corticosteroids (≤10 mg prednisone or equivalent) for at least 2 weeks prior to study treatment
- Toxicity from prior anticancer therapy not resolved to Grade ≤1 except alopecia, vitiligo, Grade ≤2 peripheral neuropathy, or stable endocrinopathies on hormone replacement
- History of Grade ≥2 immune-related adverse events with prior immunotherapy that led to discontinuation, except Grade 2 or 3 events that responded to treatment without recurrence after rechallenge; stable or resolved endocrinopathies allowed
- History of solid organ or hematologic stem cell transplantation
- Any partial or complete bowel obstruction requiring hospitalization within 30 days prior to first dose of study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Start Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
2
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
3
Centre Leon Berard
Lyon, France, 69008
Actively Recruiting
4
Institut Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
5
Hosp Univ Vall D Hebron
Barcelona, Spain, 08035
Actively Recruiting
6
Hosp. Univ. 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here